HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.

ABSTRACT:

Background

Several serological assays have been developed to detect antibodies elicited against infections with oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and subsequent HPV infection risk may differ. We compared HPV16-specific antibody levels previously measured by a virus-like particle (VLP)-based direct enzyme-linked immunoassay (ELISA) with levels measured by additional assays and evaluated the protection against HPV16 infection conferred at different levels of the assays.

Methodology/principal findings

Replicate enrollment serum aliquots from 388 unvaccinated women in the control arm of the Costa Rica HPV vaccine trial were measured for HPV16 seropositivity using three serological assays: a VLP-based

SUBMITTER: Lin SW 

PROVIDER: S-EPMC3534652 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature